Under construction – not a live service
Sign in
Taking people in TaiwanPhase 1

Tests ZW251, a new drug, in adults with advanced solid tumors

Tests ZW251 in adults with advanced liver, lung or germ cell cancers.

Key facts

Who runs it
Zymeworks BC Inc.
Where
Taipei, TaiwanSee the 2 sitesAlso in 5 other countries, 23 sites
Registry title
A Study of ZW251 in Participants With Advanced Solid Tumors
Status
Recruiting
Phase
Phase 1
People taking part
140 people, planned
Started
21 Oct 2025
Expected to end
May 2028
Type of study
Interventional
Treatments tested
  • ZW251
Record updated
5 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced liver cancer (hepatocellular carcinoma), squamous cell lung cancer, or a germ cell tumor that cannot be removed by surgery or has spread.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Locally advanced disease that cannot be removed by surgery, or disease that has spread. Measurable disease is needed. Liver cancer: Child-Pugh Class A liver function and not able to have a transplant. Germ cell tumor: mainly yolk sac and/or choriocarcinoma type. ECOG score of 0 or 1.

Main reasons for not taking part

  • Another cancer that is getting worse or needed treatment in the last year
  • Hepatic encephalopathy in the past 6 months, or medicines needed to control it
  • Gastrointestinal bleeding within 3 months
  • Uncontrolled kidney disease, pancreatitis, or non-cancer liver disease
  • Liver cancer growing into the main portal vein needs sponsor approval to join

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Pathologically or cytologically confirmed diagnosis of HCC with evidence of locally advanced (unresectable, and ineligible for transplant) and/or metastatic disease. Noninvasive methods may be used to confirm diagnosis
  • Pathologically or cytologically confirmed diagnosis of squamous cell NSCLC with evidence of locally advanced (unresectable) and/or metastatic disease
  • Pathologically or cytologically confirmed diagnosis of GCT with evidence of yolk sac and/or choriocarcinoma predominant component and locally advanced (unresectable) and/or metastatic disease
  • Measurable disease per RECIST v1.1
  • Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
  • Liver function status of Child-Pugh Class A (for HCC only)
  • Adequate organ function

Who cannot take part

  • Known additional malignancy that is progressing or that has required active treatment within the last year
  • History of hepatic encephalopathy within the past 6 months or requirement for medications to control encephalopathy
  • Known gastrointestinal bleeding within 3 months
  • Acute or chronic uncontrolled renal disease, pancreatitis, or non-malignant liver disease
  • Participants with HCC experiencing main portal vein tumor invasion require sponsor approval for enrollment

Where in Taiwan

Also in 5 other countries, 23 sites

  • National Taiwan University HospitalTaipei, TaiwanContact: Ann Lii Cheng, MD (principal investigator)Taking people
  • Taipei Veterans General HospitalTaipei, TaiwanContact: Yi-Hsiang Huang, MD, PhD (principal investigator)Taking people

About the trial

What the trial wants to find out

The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell non-small cell lung cancer (NSCLC), or germ cell tumors (GCT).

The group in the trial

  • ZW251Treatment being tested

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A First-In-Human, Phase 1, Open-Label, Multicenter Study of ZW251, a Novel Glypican-3 Targeting Antibody-Drug Conjugate, in Participants With Advanced Solid Tumors, Including Hepatocellular Carcinoma
Plain-language title
Tests ZW251, a new drug, in adults with advanced solid tumorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
5 October 2026